image:Justin Schaal, PhD, assistant professor of research pathology at the Keck School of Medicine of USC view more

Credit: USC photo/ Ricardo Carrasco III

Somewhere along the long and winding road of evolution, our ancestors lost the ability to produce a small but mighty group of molecules called theta-defensins that help fight bacterial infections.

More than seven million years later, researchers at the Keck School of Medicine of USC are creating new-and-improved versions of these molecules as a potential way to treat antibiotic resistant superbugs.

The research, just published in Scientific Reports, was led by Justin Schaal, PhD,an assistant professor of research pathology at the Keck School of Medicine. The paper describes the development of a new, bio-inspired molecule that is highly effective in clearing bacterial infections in an animal model. Importantly, the molecule does not act as an antibiotic, but rather as an immune stimulant, representing a new way to treat life-threatening antibiotic resistant infections.

The need for alternatives to antibiotics

Since their introduction more than 70 years ago, antibiotics have been the standard of care for bacterial infections. Despite dozens of varieties, almost all work by killing bacteria directly or by blocking their ability to proliferate.

This is the root cause of antibiotic resistance, Schaal said. Bacteria have an immense ability to evolve rapidly, which gives them power to overcome direct-acting antibiotic molecules.

Over the past two decades, an increasing number of bacteria have become resistant to all but the most powerful antibiotics. Several groups of such superbugs exist, including Carbapenem-resistant Enterobacteriaceae (CRE). CRE, which include certain strains ofE. coliandKlebsiella pneumoniae, are resistant to the class of antibiotics known as carbapenemsa last resort option for many patients with persistent infections. According to the Centers for Disease Control and Prevention, in the U.S. alone, CRE superbugs represent an increasing fraction of the more than 140,000 deadly or life-threatening infections caused by species of Enterobacteriaceae.

To address this urgent threat to human health, the National Institutes of Health (NIH) challenged researchers to find new strategies to combat antibiotic resistant bacteria. Building on pioneering research on theta-defensins led by Michael Selsted, MD, PhD, chair and professor of pathology, Schaal and his colleagues got to work.

Bioengineering molecules to work like theta-defensins

Using as inspiration RTD-1, a naturally occurring theta-defensin found in old-world monkeys such as baboons and rhesus monkeys, the researchers bioengineered similar molecules and screened them for their ability to fight Klebsiella infections in a mouse model. The most potent peptide they created, a highly stable cyclic peptide called MTD12813, is 10 times more efficient than RTD-1 in clearing infections.

While more work is needed to determine exactly how MTD12813 works, the researchers know it activates the immune systemspecifically cells called macrophages and neutrophils that engulf and destroy pathogens. The peptide also modulates the immune response, reducing poorly regulated inflammation that often occurs when the body fights a bacterial infection.

We call this peptide a host-directed anti-infective because rather than kill the bacteria directly like traditional antibiotics, it stimulates the hostusto fight the infection, Schaal said.

Through a licensing agreement with USC, the technology will now be developed further in partnership withOryn Therapeutics.

Based on this and related research conducted at USC, Oryn is developing a novel class of macrocyclic peptides as therapeutics for unmet needs in autoimmune and inflammatory diseases, infectious diseases, and cancer. We are quite optimistic about the prospects for turning the important scientific advances reported in this publication into successful treatments for increasingly dangerous bacterial infections, said Robert Erwin, Oryns Chief Executive Officer.

Selsted said the timing for the development of this technology is right, given current concerns that the next pandemic may be bacterial in nature.

This new discovery of how to stimulate host clearance of bacteria is really timely, he said.

About the study

The title of the paper is A host-directed macrocyclic peptide therapeutic for MDR gram-negative bacterial infections. Additional authors are Yoshihiro Eriguchi, Dat Q. Tran, Patti A. Tran, Chase Hawes, Anthony E. Cabebe, Kaitlyn Pike, Katie Trinh, and Andr J. Ouellette, all from the Keck School of Medicine of USC.

The work was supported by grants from the National Institutes of Allergy and Infectious Diseases (RO1 AI22931, R01 AI125141), the National Institute of Dental and Craniofacial Research (R01DE021341), the Southern California Clinical and Translational Science Institute (UL1 TR000130 ), and the National Cancer Institute (P30 CA014089).

About Keck School of Medicine

Founded in 1885,theKeck School of Medicine of USCis one of the nations leading medical institutions, known forinnovative patient care, scientific discovery, education and community service. Medical and graduate students work closely with world-renowned faculty and receive hands-on training in one of the nations most diverse communities. They participate in cutting-edge research as they develop into tomorrows health leaders. With 1200 resident physicians across 70 specialty and subspecialty programs, the Keck School is the largest educator of physicians practicing in Southern California.

Scientific Reports

Experimental study

Animals

A host-directed macrocyclic peptide therapeutic for MDR gram-negative bacterial infections

6-Dec-2021

Selsted is a co-founder and Chief Scientific Officer of Oryn Therapeutics, LLC (Oryn). He is an equity holder but receives no income from Oryn. Tran is the Scientific Director of Oryn and is an equity holder. Ouellette is an equity holder in Oryn but receives no income. Oryn has licensed technology described in this publication from the University of Southern California and the relationship between Oryn and USC is disclosed to and approved by all parties. All other authors declare no competing interests.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more from the original source:
Boosting the body's response to infections with a bio-inspired peptide - EurekAlert